

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): Amorphous celecoxib, wherein said amorphous celecoxib exhibits a glass transition measurable by differential scanning calorimetry.

Claims 2-14 (cancelled).

Claim 15 (currently amended): A pharmaceutical composition comprising amorphous celecoxib in a total celecoxib dosage amount of about 10 mg to about 1000 mg, and one or more pharmaceutically acceptable excipients, wherein said amorphous celecoxib exhibits a glass transition measurable by differential scanning calorimetry.

Claims 16-35 (cancelled).

Claim 36 (new): Amorphous celecoxib as set forth in claim 1 having a C_{\max} greater than the C_{\max} of crystalline celecoxib.

Claim 37 (new): Amorphous celecoxib as set forth in claim 1 having an AUC greater than the AUC of crystalline celecoxib.